<SEC-DOCUMENT>0001140361-23-005696.txt : 20230210
<SEC-HEADER>0001140361-23-005696.hdr.sgml : 20230210
<ACCEPTANCE-DATETIME>20230210060703
ACCESSION NUMBER:		0001140361-23-005696
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230210
DATE AS OF CHANGE:		20230210
GROUP MEMBERS:		ALEXANDER J. DENNER, PH.D.
GROUP MEMBERS:		LOUIS STERLING III

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-52399
		FILM NUMBER:		23608446

	BUSINESS ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sarissa Capital Management LP
		CENTRAL INDEX KEY:			0001577524
		IRS NUMBER:				900924432
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
		BUSINESS PHONE:		203-302-2330

	MAIL ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>ny20006859x17_sc13da.htm
<DESCRIPTION>SC 13D/A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND
      EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Washington,
      D.C. 20549</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SCHEDULE 13D</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Under the
      Securities Exchange Act of 1934</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">(Amendment No.
      7)*</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z20353a0314c34a3c8a38ff91c3781bad" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-style: normal; font-variant: normal; text-transform: none;">
            <div style="text-align: center;">Amarin Corporation plc</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: center;">(Name of Issuer)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Ordinary Shares, par value 50 pence per share</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: center;">(Title of Class of Securities)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">023111206</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: center;">(CUSIP Number)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z5c5f236256144ee799ff2dc9d28a46d1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Mark DiPaolo</div>
            <div style="text-align: center;">Senior Partner, General Counsel</div>
            <div style="text-align: center;">Sarissa Capital Management LP</div>
            <div style="text-align: center;">660 Steamboat Road</div>
            <div style="text-align: center;">Greenwich, CT 06830</div>
            <div style="text-align: center;">203-302-2330</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: center;">(Name, Address and Telephone Number of Person</div>
            <div style="text-align: center;">Authorized to Receive Notices and Communications)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">February 9, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: center;">(Date of Event which Requires Filing of this Statement)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g),
      check the following box. &#9744;</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">Note:</font>&#160; Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies
      are to be sent.</div>
    <div><br>
    </div>
    <div>*The remainder of this cover page shall be filled out for a reporting person&#8217;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures
      provided in a prior cover page.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The information required on the remainder of this cover page shall not be deemed to be &#8220;filed&#8221; for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that
      section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).</div>
    <div><br>
    </div>
    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="margin-bottom: 8pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb429186cc9164c0980f8283a76b36e62" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50.96%; vertical-align: top;">
            <div>CUSIP No. 023111206</div>
          </td>
          <td style="width: 49.04%; vertical-align: top;">
            <div style="text-align: right;">Page 2 of 4 Pages</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center;">SCHEDULE 13D</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This Amendment No. 7 to Schedule 13D (&#8220;Amendment No. 7&#8221;) relates to American Depositary Shares (&#8220;ADS(s)&#8221;), each ADS representing one ordinary share, par value 50 pence per share (the &#8220;Ordinary Shares&#8221;), issued by
      Amarin Corporation plc, a company incorporated under the laws of England and Wales (the &#8220;Issuer&#8221;), and amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on January 24, 2022 (the &#8220;Initial
      Schedule 13D&#8221;), as amended by Amendment No. 1 to Schedule 13D filed on June 3, 2022, Amendment No. 2 to Schedule 13D filed on June 16, 2022, Amendment No. 3 to Schedule 13D filed on October 11, 2022, Amendment No. 4 to Schedule 13D filed on January
      11, 2023, Amendment No. 5 to Schedule 13D filed on January 19, 2023 and Amendment No. 6 to Schedule 13D filed on February 8, 2023 (the Initial Schedule 13D as so amended, the &#8220;Schedule 13D&#8221;). All capitalized terms contained herein but not otherwise
      defined shall have the meanings ascribed to such terms in the Schedule 13D.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This Amendment No. 7 is being filed to amend Item 4 and Item 7 as follows:</div>
    <div><br>
    </div>
    <div>
      <table class="DSPFListTable" id="zf9b6616702304eec8bb0a7fa08cdd869" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold;">Item 4.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;"><font style="font-weight: bold;">Purpose of Transaction. </font>Item 4 of the Schedule 13D is hereby amended to include the following:</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">On February 9, 2023, Sarissa Capital issued the press release attached as Exhibit 10 hereto.</div>
    <div><br>
    </div>
    <div>
      <table class="DSPFListTable" id="zf31350b179e84aba832ab5f4ed08ed7d" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">Item 7.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;">Material to Be Filed as Exhibits. </font>Item 7 of the Schedule 13D is hereby amended to include the following:</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>Exhibit 10 &#8211; Press Release, February 9, 2023</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="margin-bottom: 8pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z370c9614ac3e41ce949b11d6f875b81c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50.96%; vertical-align: top;">
            <div>CUSIP No. 023111206</div>
          </td>
          <td style="width: 49.04%; vertical-align: top;">
            <div style="text-align: right;">Page 3 of 4 Pages</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center;">SCHEDULE 13D</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURE</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.</div>
    <div><br>
    </div>
    <div>Dated: February 10, 2023</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf502f99a5ce3457eac5a35410e7dd836" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div>SARISSA CAPITAL MANAGEMENT LP</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top; padding-bottom: 2px;">
            <div>By:</div>
          </td>
          <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Mark DiPaolo<br>
            </div>
          </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;">
            <div>Name: Mark DiPaolo</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;">
            <div>Title:&#160;&#160; Senior Partner, General Counsel</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Alexander J. Denner</div>
          </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div>Alexander J. Denner</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Louis Sterling III</div>
          </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div>Louis Sterling III</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="margin-bottom: 8pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z20cdb7e2135a47f08bf8e097b5437bd2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50.96%; vertical-align: top;">
            <div>CUSIP No. 023111206</div>
          </td>
          <td style="width: 49.04%; vertical-align: top;">
            <div style="text-align: right;">Page 4 of 4 Pages</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center;">SCHEDULE 13D</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INDEX TO EXHIBITS</div>
    <div><br>
    </div>
    <div><a href="https://www.sec.gov/Archives/edgar/data/897448/000089914022000088/s49762134b.htm">Exhibit 1</a> &#8211; Joint Filing Agreement of the Reporting Persons*</div>
    <div><br>
    </div>
    <div><a href="https://www.sec.gov/Archives/edgar/data/897448/000089914022000563/53826129b.htm">Exhibit 2</a> &#8211; Press Release, June 15, 2022*</div>
    <div><br>
    </div>
    <div><a href="https://www.sec.gov/Archives/edgar/data/897448/000119312522260662/d399645dex3.htm">Exhibit 3</a> &#8211; Press Release, October 11, 2022*</div>
    <div><br>
    </div>
    <div><a href="https://www.sec.gov/Archives/edgar/data/897448/000089914023000032/s58919650b.htm">Exhibit 4</a> &#8211; Requisition Notice, January 10, 2023*</div>
    <div><br>
    </div>
    <div><a href="https://www.sec.gov/Archives/edgar/data/897448/000089914023000032/s58919650c.htm">Exhibit 5</a> &#8211; Press Release, January 10, 2023*</div>
    <div><br>
    </div>
    <div><a href="https://www.sec.gov/Archives/edgar/data/897448/000089914023000032/s58919650d.htm">Exhibit 6</a> &#8211; Joint Filing Agreement of the Reporting Persons*</div>
    <div><br>
    </div>
    <div><a href="https://www.sec.gov/Archives/edgar/data/897448/000089914023000032/s58919650e.htm">Exhibit 7</a> &#8211; Power of Attorney Granted by Louis Sterling III in favor of Mark DiPaolo and Patrice Bonfiglio, January 10, 2023*</div>
    <div><br>
    </div>
    <div><a href="https://www.sec.gov/Archives/edgar/data/897448/000114036123002125/ny20006859x3_ex-8.htm">Exhibit 8</a> &#8211; Press Release, January 18, 2023*</div>
    <div><br>
    </div>
    <div><a href="https://www.sec.gov/Archives/edgar/data/897448/000114036123005127/ny20006859x11_ex9.htm">Exhibit 9</a> &#8211; Press Release, February 7, 2023*</div>
    <div><br>
    </div>
    <div><a href="ny20006859x17_ex10.htm">Exhibit 10</a> &#8211; Press Release, February 9, 2023</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 1px; width: 20%; color: #000000; background-color: #000000; margin-left: 0px; margin-right: auto; border: none;" align="left" noshade="noshade"> </div>
    <div>
      <table class="DSPFListTable" id="z83a1aaffac8443cda840b70fd134f84f" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 18pt;">
              <div style="text-align: left;">*</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">Previously filed.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>ny20006859x17_ex10.htm
<DESCRIPTION>EXHIBIT 10
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; text-align: left;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 9pt; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> EXHIBIT 10<br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 9pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 9pt; font-weight: bold;">SARISSA CAPITAL DOES NOT BELIEVE AMARIN CARES ABOUT SHAREHOLDERS</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Amarin Continues to Ignore the Loud and Clear Message Sent by Shareholders at the Last Shareholder Meeting</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Amarin&#8217;s Misleading Words Cannot Hide Its Poor Leadership and Governance Practices That Harm and Disenfranchise Shareholders</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Vote the <font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 32, 96); font-style: normal; font-variant: normal; text-transform: none;">BLUE</font> proxy card &#8220;FOR&#8221; the appointment of the Sarissa Nominees and &#8220;FOR&#8221; the Removal of Chairman Per Wold-Olsen <u>on or before February 21, 2023</u></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Greenwich, CT, February 9, 2023 &#8211; Sarissa Capital Management LP (&#8220;Sarissa&#8221;) today issued the following letter to other shareholders of Amarin Corporation plc
      (NASDAQ: AMRN):</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Dear Fellow Amarin Shareholders:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">We, the owners, face an important decision at our upcoming shareholder meeting. Amarin has an incredibly valuable asset in Vascepa/Vazkepa, but the company continues to destroy
      value by mismanagement and poor capital allocation decisions. The company is in dire need of change, which even current leadership recognizes. And shareholders sent a loud and clear message in support of change at the annual meeting. However, the
      board spends millions of dollars of precious shareholder capital to keep shareholders off the board. Inexplicably, the board does not welcome the positive participation of its largest shareholder with a stellar track record of success.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Amarin is at a critical juncture and risks further destruction of value unless we shareholders enact change now. Sarissa is seeking to remake the board by adding shareholder
      representatives who we believe will help maximize shareholder value and by removing Chairman Per Wold-Olsen. Our slate, including Sarissa candidates that helped turn around The Medicines Company until its ultimate sale for nearly $10 billion, has the
      qualifications and experiences to help Amarin reach its true potential.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Sarissa urges shareholders to vote the <font style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 32, 96); font-style: normal; font-variant: normal; text-transform: none;">BLUE</font> proxy card &#8220;FOR&#8221; the appointment of the Sarissa Nominees and &#8220;FOR&#8221; the Removal of Chairman Per Wold-Olsen <font style="font-weight: bold;"><u>on or before February 21, 2023</u></font>.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">As the general meeting approaches, we ask fellow shareholders separate Amarin&#8217;s words from its actions. As we all know, actions speak louder than words. The actions of &#8220;new
      Amarin&#8221; are marked by the same poor performance, missed goals and blatant disregard for shareholders as the &#8220;old Amarin.&#8221; Amarin&#8217;s words are filled with inaccurate statements, empty promises and a lack of accountability.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Amarin has the audacity to state publicly, &#8220;the Company made solid progress in 2022, against its strategic objectives&#8221; even though 2022 was terrible for
      shareholders by any objective measure:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf2b9d6027861447d9baa172030a463c9" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">In 2022, Amarin&#8217;s stock price declined over 64%, wiping out more than $840 million of shareholder value.*</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z123a8eb48dfb4fac9b36ffa615a0cfa0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">In June 2022, Amarin was 6 months late in announcing cost cuts in the US after a third generic entered and disrupted the market in January 2022. Entrance of the third generic was
              expected. The shareholder capital wasted due to the delay was an immense and avoidable destruction of shareholder value.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3e0586b95e5f4f1c818e2f8d4fd02c3e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">The European launch is off to a terrible start. Management could not convince Germany to reimburse Vazkepa even though, with the use of Vazkepa, Germany could save a significant portion
              of the &gt;&#8364;28 billion that it spends annually on cardiovascular disease.<sup style="font-family: Roboto, Arial; vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup> The rest of Europe is behind schedule, failing to live up
              to management&#8217;s earlier promises.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Amarin&#8217;s proclamation that its &#8220;Commitment to High Standards of Corporate Governance Drives Alignment and Accountability&#8221; is inconsistent with their treatment
      of shareholders as Amarin has demonstrated time and time again that it dismisses shareholder interests:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7bc55ace69584a6b8ba650bebf4d0145" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">The board continues to completely ignore the outcome of the most recent annual meeting where nearly 50% of all votes cast were either votes against the Amarin board or abstentions.&#160;
              Notably, this result occurred after Sarissa publicly stated that &#8220;we intend to vote &#8216;ABSTAIN&#8217; as this reinforces our message that change is needed as we give the board time to add shareholder representatives.&#8221;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> &#8225;</sup> Yet, the board still refuses to add Sarissa representatives.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdb79cbd5af4648378c56e448ae687ed4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">We believe the board&#8217;s prolonged &#8220;board refreshment process&#8221; was not legitimate. No shareholder representatives were added to the board and our input was never sought on any of their
              appointees. Sarissa is Amarin&#8217;s largest shareholder, and we have a track record of creating shareholder value through board representation, including in the cardiovascular space. It is bewildering that Amarin remains obstinate and will not
              allow shareholder participation on the board.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z556b527f037f4224afdf72a3cc8b6c75" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Amarin disclosed that it has spent more than $4 MILLION of shareholder capital and is planning to spend &gt;$7 MILLION total to prevent its largest shareholder from obtaining
              representation on the board. This amount is a whopping ~6X more than what Sarissa intends to spend in this proxy contest. Either Amarin does not know how to spend money efficiently or does not care about shareholders&#8217; money.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Amarin&#8217;s assertion that &#8220;New Management Has Made Engagement a Top Priority&#8221; is far from the truth as Amarin continues to make it difficult for shareholders,
      who are frustrated, to have a voice:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z93c2112ab03f4d6faf1e772ac6669686" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">The board does not engage meaningfully with its shareholder base. Historically, barely 50% of the shareholders show up at any given shareholder meeting. Chairman Wold-Olsen and other
              directors have been dismissive of Amarin&#8217;s shareholders as a &#8220;retail&#8221; shareholder base. &#8220;Retail&#8221; shareholders are owners of Amarin and are entitled to have their voices heard.</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z192e7eb8ee764c4c8f8b7783049c748f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Amarin delayed the disclosure of the record date for the general meeting, artificially established an earlier than necessary cut-off time for voting and delayed delivery of crucial
              shareholder lists requested by Sarissa. We believe Amarin&#8217;s board is employing these tactics to uneven the playing field so that shareholders are unable to voice their dissatisfaction with the current regime. Amarin claims that these
              timelines are all required by UK law, which is canonically false, and they know it!</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7e949014a56c4cce92b7265b3b6a5a9a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Amarin has continuously misrepresented its interactions with Sarissa and Sarissa&#8217;s track record of success as it attempts to smear us and our nominees. In our presentations, we exposed
              Amarin&#8217;s misstatements, disinformation, and dishonesty, including by providing detailed accounts of our correspondence. Amarin attempts to sully our track record using wrong and misleading metrics. In fact, the average performance of our
              larger positions during the tenure of Sarissa and Sarissa designees is +39.7%.&#167; In contrast, Amarin&#8217;s performance under CEO Karim Mikhail and Chairman Per Wold-Olsen were -70.8% and -62.8% to year end 2022 respectively.<sup style="font-family: 'Cambria Math', serif; vertical-align: text-top; line-height: 1; font-size: smaller;">&#8214;</sup> Amarin maintains that &#8220;we don&#8217;t need Sarissa to maximize value.&#8221; Again, actions speak louder than words.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Amarin is in dire need of change. Sarissa believes the current regime is wasting a uniquely valuable opportunity. Vascepa is a highly attractive asset that can not only
      meaningfully improve patients&#8217; lives by reducing cardiovascular events but also save significant money for health systems worldwide. The board, led by Chairman Wold-Olsen, has failed shareholders and takes no accountability for its failures. Sarissa
      urges shareholders to act now to support change so that the current leadership does not continue its misguided stewardship of shareholder capital.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">We look forward to continuing our engagement with our fellow shareholders. Thank you for your continued support.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Sarissa Capital Management LP</div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">#FreeAmarin</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Visit our website at <u>www.freeamarin.com</u>&#160;for helpful information about Sarissa and the need for change at Amarin.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Vote the <font style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 32, 96); font-style: normal; font-variant: normal; text-transform: none;">BLUE</font>&#160;proxy

      card &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Sarissa Nominees and &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the removal of Chairman Per Wold-Olsen.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The General Meeting of Amarin shareholders is scheduled for February 28, 2023, BUT TO MAKE SURE YOUR VOTE COUNTS, <font style="font-weight: bold;"><u>SUBMIT YOUR VOTE ON OR
          BEFORE TUESDAY, FEBRUARY 21, 2023</u></font>.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Shareholders should be receiving the <font style="font-weight: bold; color: rgb(0, 32, 96); background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">BLUE</font>&#160;proxy card this week. If you do not receive your <font style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 32, 96); font-style: normal; font-variant: normal; text-transform: none;">BLUE</font>&#160;proxy

      card this week or have any questions on how to vote, please contact:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">D.F. King &amp; Co., Inc.</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">48 Wall Street</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">New York, New York 10005</div>
    <div style="text-align: center; font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Shareholders call toll-free:</font> (800) 331-7024</div>
    <div style="text-align: center; font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Banks and Brokers call:</font> (212) 269-5550</div>
    <div style="text-align: center; font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">By Email:</font> <u>AMRN@dfking.com</u></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">* Calculated from end of day December 31, 2021 &#8211; December 30, 2022. Source: Bloomberg</div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><sup style="font-family: Roboto, Arial; vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup> European Cardiovascular Disease Statistics 2017 edition</div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8225; </sup>Sarissa Capital Press Release June 15, 2022: <u>https://www.businesswire.com/news/home/20220615006073/en/Sarissa-Capital-Intends-to-Vote-%E2%80%9CAbstain%E2%80%9D-at-the-Amarin-Annual-Meeting</u></div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#167; Calculated as average price change where a Sarissa or Sarissa-affiliated director held tenure as a board member, for larger Sarissa portfolio positions defined as (&#8805;$50M),
      between the date immediately preceding their first date-in service and 12/30/2022. Not weighted by investment and not indicative of Sarissa&#8217;s investment returns</div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8214;</sup> Calculated as price change between the dates 7/30/2021 and 12/30/2022 for CEO Karim Mikhail and
      1/7/2022 and 12/30/2022 for Per Wold-Olsen</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zced921327b4b4d6995c0da01732bcdb6" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">Contact:</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Jean Puong</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaad14278761047718e5d275a21204cd3" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Sarissa Capital Management LP</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1d0abbf260064428b9dd0f22cbf1a2e5" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">info@sarissacap.com</div>
          </td>
        </tr>

    </table>
    <br>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Additional Information</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on
      January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc (the &#8220;Company&#8221;) at the general meeting of the Company for the election of Sarissa Capital&#8217;s slate of highly-qualified nominees (the &#8220;General Meeting&#8221;).
      Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The definitive proxy statement and other relevant documents are available at no charge on the SEC&#8217;s website at <u>www.sec.gov</u> and at <u>www.freeamarin.com</u>. The
      definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital&#8217;s proxy solicitor, D.F. King &amp; Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free:
      (800) 331-7024).
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
